THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Abdulrafeh Naqash to Humans

Back to Details
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Humans.
Abdulrafeh Naqash
Connection Strength
0.710
Humans
  1. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023 Oct; 11(10).
    View in: PubMed
    Score: 0.051
  2. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022 10 10; 40(29):3439-3452.
    View in: PubMed
    Score: 0.046
  3. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021 Dec 01; 7(12):1856-1861.
    View in: PubMed
    Score: 0.045
  4. Why Are Randomization and Placebos Included in Many Cancer Trials? JAMA Oncol. 2021 07 01; 7(7):1080.
    View in: PubMed
    Score: 0.043
  5. The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Hum Vaccin Immunother. 2021 07 03; 17(7):1935-1939.
    View in: PubMed
    Score: 0.042
  6. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 Jul; 69(7):1177-1187.
    View in: PubMed
    Score: 0.040
  7. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer. 2019 07 05; 7(1):169.
    View in: PubMed
    Score: 0.038
  8. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019 01 08; 7(1):4.
    View in: PubMed
    Score: 0.036
  9. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol. 2018 06; 57(6):867-872.
    View in: PubMed
    Score: 0.034
  10. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018 05; 57(5):705-708.
    View in: PubMed
    Score: 0.034
  11. Hemophagocytic lymphohistiocytosis (HLH) secondary to Ehrlichia chaffeensis with bone marrow involvement. Ann Hematol. 2017 10; 96(10):1755-1758.
    View in: PubMed
    Score: 0.033
  12. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. Acta Oncol. 2017 10; 56(10):1327-1330.
    View in: PubMed
    Score: 0.032
  13. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist. 2022 Sep 02; 27(9):778-789.
    View in: PubMed
    Score: 0.012
  14. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 08 15; 128(16):3067-3079.
    View in: PubMed
    Score: 0.012
  15. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.012
  16. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
    View in: PubMed
    Score: 0.011
  17. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022 10; 76(4):1000-1012.
    View in: PubMed
    Score: 0.011
  18. Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology. 2022; 11(1):2017162.
    View in: PubMed
    Score: 0.011
  19. Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist. 2021 10; 26(10):e1883-e1886.
    View in: PubMed
    Score: 0.011
  20. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 12; 20(12):2577-2584.
    View in: PubMed
    Score: 0.011
  21. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
    View in: PubMed
    Score: 0.011
  22. Advances in the management of alveolar soft part sarcoma. Curr Probl Cancer. 2021 08; 45(4):100775.
    View in: PubMed
    Score: 0.011
  23. Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. Acta Oncol. 2021 06; 60(6):813-817.
    View in: PubMed
    Score: 0.011
  24. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
    View in: PubMed
    Score: 0.011
  25. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.011
  26. Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer? JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.011
  27. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 12 01; 6(12):1952-1956.
    View in: PubMed
    Score: 0.010
  28. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.010
  29. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583.
    View in: PubMed
    Score: 0.010
  30. Reply to J. Delyon et al. J Clin Oncol. 2019 12 20; 37(36):3564-3565.
    View in: PubMed
    Score: 0.010
  31. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745.
    View in: PubMed
    Score: 0.009
  32. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci. 2018 Nov 07; 19(11).
    View in: PubMed
    Score: 0.009
  33. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr; 25(3):551-557.
    View in: PubMed
    Score: 0.008
  34. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol. 2016 Jul; 97(1):9-16.
    View in: PubMed
    Score: 0.008
  35. Epigenetics: A primer for clinicians. Blood Rev. 2016 07; 30(4):285-95.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES